PharmaCyte Biotech, Inc.

- 05 OCT 2015
Imaging Endpoints Founder Discusses Role in PharmaCyte Biotech’s Unique Approach to Pancreatic Cancer for Upcoming Clinical Trial
SILVER SPRING, MD, October 5, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the third in a series of articles that will serve to educate the public on its technology and
Read more →
- Posted in
- News
- 01 OCT 2015
PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers
SILVER SPRING, Md., October 1, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box ®, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and
Read more →
- Posted in
- News
- 28 SEP 2015
PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need
SILVER SPRING, MD, September 28, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, released today the second in a series of articles that will serve to educate the public on its technology and how
Read more →
- Posted in
- News
- 25 SEP 2015
PharmaCyte Biotech Hires Industry-Leading Firm to Assist with Investigational New Drug Application
SILVER SPRING, MD, September 25, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes announced today that it has contracted with Chamow & Associates, located in the San Francisco Bay Area, to assist with the Chemistry, Manufacturing and Control (CMC) regulatory
Read more →
- Posted in
- News
- 23 SEP 2015
PharmaCyte Biotech Discusses Pancreatic Cancer Treatment for Upcoming Phase 2b Human Clinical Trial
SILVER SPRING, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the first in a series of articles that will serve to educate the public on its technology and how
Read more →
- Posted in
- News
- 09 SEP 2015
PharmaCyte Biotech Begins Phase 2b Clinical Trial Push With Imaging Endpoints Contract for Radiological Imaging
SILVER SPRING, Md., Sept. 09, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has contracted with Imaging Endpoints in Scottsdale, Arizona, to perform radiologic imaging that will be required for
Read more →
- Posted in
- News
- 02 SEP 2015
PharmaCyte Biotech Executives Interviewed on Role of Leaders in Oncology for Development of Its Clinical Trials
SILVER SPRING, Md., Sept. 02, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, JD, and Chief Operating Officer, Dr. Gerald W. Crabtree, Ph.D., have
Read more →
- Posted in
- News
- 25 AUG 2015
PharmaCyte Biotech Announces Successful Completion of Interim Audit of GMP Facility for the Production of Cell-in-a-Box for Clinical Trials
SILVER SPRING, MD, August 25, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, provided an update on the progress of completing the compliance process for Austrianova’s cGMP (current Good Manufacturing Practices-compliant) facility in
Read more →
- Posted in
- News
- 06 AUG 2015
PharmaCyte Biotech Updates Progress of cGMP Facility for the Production of Cell-in-a-Box for Clinical Trials
SILVER SPRING, MD, August 6, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced an update on the progress of completing the certification of Austrianova’s cGMP (current Good Manufacturing Practices-compliant) facility in the
Read more →
- Posted in
- News
- 04 AUG 2015
Chardan Releases Industry Report Covering PharmaCyte Biotech
SILVER SPRING, MD, August 4, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chardan Capital Markets LLC, a privately held full service global investment bank specializing in micro, small and
Read more →
- Posted in
- News

Press Releases